New Therapies of Liver Diseases

• Autore: Toniutto Pierluigi
• Pubblicazione: Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
• Descrizione fisica: 1 online resource (236 p.)
• Soggetto topico: Public health and preventive medicine
• Soggetto non controllato: acute-on-chronic liver failure; acute-on-chronic liver failure (ACLF); alcoholic hepatitis; alpha-fetoprotein; ammonia; anti-mineralocorticoids; antivirals; ascites; autoantibodies; bleeding; cholangiocarcinoma; cirrhosis; cirrhotic ascites; clinical trials; colorectal cancer metastases; decompensated cirrhosis; decompensation; effective hypovolemia; Farnesoid X Receptor (FXR) agonist; functional cure; furosemide; HBV; HDV; hepatocellular carcinoma; human albumin; humoral response; immunosuppressant; immunotherapy; infection; liver cancer; liver injury; liver transplantation; liver transplantation (LT); loop diuretics; Milan criteria; n/a; non-selective beta-blockers; Pan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists; pharmacology; portal hypertension; portal-systemic shunt; primary biliary cholangitis; primary biliary cholangitis (PBC); primary sclerosing cholangitis (PSC); real-world; rifaximin; SARS-CoV-2; second line therapy; solid organ transplantation; statins; survival; survival rate; systemic treatment; targeted therapy; TIPS; tolvaptan; treatment response; unresectable hepatocellular carcinoma; ursodeoxycholic acid; ursodeoxycholic acid (UDCA); vaccination; vaptans; varices; vigilance
• Persona (resp. second.): ToniuttoPierluigi
• Sommario/riassunto: In this Special Issue of the journal, advancements in the treatment of liver diseases are illustrated by international experts in the field. New treatment options for primary biliary cirrhosis and, hopefully, primary sclerosing cholangitis are discussed. Up-to-date pharmacological therapy for preventing liver cirrhosis decompensation and treating acute-on-chronic liver failure is highlighted. Furthermore, new treatments for cholangiocarcinoma, based on biological and tissue markers, will be available in the near future, aiming to surpass the current unsatisfactory results of traditional therapies. Immunotherapy has been applied to hepatocellular carcinoma (HCC). The new first-line treatment, combining atezolizumab plus bevacizumab for HCC in the intermediate and advanced stages, will allow for an increase in patient survival in the near future. Liver transplantation (LT) remains the preferred treatment for many patients with end-stage liver diseases and HCC. The selection criteria for LT in patients with HCC moved from morphological to dynamic criteria, such as those derived from the assessment of tumor responses to locoregional and/or systemic treatments before transplantation. This allowed many patients who would have been excluded from a transplantation with the old selection criteria to access one. Finally, a very interesting issue regarding new indications for liver transplantation is illustrated.
• Titolo autorizzato: New Therapies of Liver Diseases
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910566457403321
• Lo trovi qui: Univ. Federico II